Allogeneic CAR T cells carry a higher risk of immune rejection, which may limit persistence and therapeutic efficacy. The authors here show that co-expression of an anti-rejection CD70 CAR with a CD19 CAR enhances persistence and activity in preclinical models of cancer and autoimmune disease.
- Kristen Zhang
- Zhe Li
- Elvin J. Lauron
